VINCASAR PFS Drug Patent Profile
✉ Email this page to a colleague
When do Vincasar Pfs patents expire, and what generic alternatives are available?
Vincasar Pfs is a drug marketed by Teva Parenteral and is included in one NDA.
The generic ingredient in VINCASAR PFS is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
Summary for VINCASAR PFS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 93 |
Patent Applications: | 4,626 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VINCASAR PFS at DailyMed |
Recent Clinical Trials for VINCASAR PFS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical College of Wisconsin | Phase 1 |
Yazeed Sawalha | Phase 1 |
Montefiore Medical Center | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for VINCASAR PFS
US Patents and Regulatory Information for VINCASAR PFS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Parenteral | VINCASAR PFS | vincristine sulfate | INJECTABLE;INJECTION | 071426-001 | Jul 17, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |